Lipoxen Share Discussion Threads

[rkhl] 24/8/2010 08:49

Good point 123asd you may be right there, maybe they were delayed buys and there is plenty of stock floating around which is why it marginally ticked up.

[123asd] 24/8/2010 03:40

rkhl - looks like those two 500k trades were delayed buys from 2pm, and they were responsible for the tick up on the offer at that time.

[rkhl] 23/8/2010 22:47

1m sells, didn't move the price, can only assume these sells have been in the background for a while helping to push the price down.

It doesn't help that RHPS recommeded a sell, PI's seem to be drifting away from this in a steady stream and not great to have an institution selling although that means nothing. (I have seen institutions buy into different shares recently and lose over 90% of their value in a few months so what do they know. It's not really an indicator either way).

As long as the phase 2 trials are positive then I see no problem here.

[ohisay] 23/8/2010 16:38

If the results are anything like good the current market cap of under £10m will look pretty cheap.

[rkhl] 23/8/2010 15:52

Waiting for the results of the phase 2 trial for Erepoxen, results should be due any day now. Was supposed to be early Q3 so looks like there may be a hold up. Guess we'll hear something soon.

http://www.proactiveinvestors.co.uk/companies/news/13844/lipoxen-and-serum-
institute-of-india-start-phase-ii-trial-for-erepoxen-13844.html

[daytraders] 19/8/2010 18:15

dam sale gone through today at 5.78p this is bad.

[rkhl] 16/8/2010 14:28

Heading towards recent lows, wasn't news meant to come early q3, anyone got any info on what is happening with the trials.

[rkhl] 28/7/2010 15:41

Oh dear, resting on 7p - not a good sign.

[rkhl] 26/7/2010 14:01

Cleared seller!?

[ohisay] 26/7/2010 12:43

Life/old/dog .?

Any ideas about todays rise anyone.

[rkhl] 01/7/2010 08:46

Have looked on the iii thread and no one went to the AGM either. Just done a dummy sell bid, was offered 7.25, looks like mm's are holding plenty of stock at the moment.

Market generally awful.

[rkhl] 30/6/2010 18:10

Anyone make it to the AGM!? and prepared to comment as well!?

[buywell2] 22/6/2010 10:22

My understanding was that Baxter was due to decide who git this work in 2010


Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, is pleased to provide an update on its partnership with Baxter
International Inc., ("Baxter"). This exclusive world-wide development and
licence agreement is based on the PolyXen PSA-Factor VIII project being
developed with Baxter, a world leader in the treatment of haemophilia, for
improved longer-acting forms of blood-clotting factors

[eternaloptimist] 22/6/2010 08:13

Lipoxen presenting at EPIC Biotech conference in London 23rd June

[drewz] 21/6/2010 11:43

Keep buying.

10-bagger potential here over 5 years. Maybe 3 years with a fair wind.

[buywell2] 21/6/2010 10:01

Further PolyXen® Technology Patent



TIDMLPX

RNS Number : 9059N
Lipoxen PLC
21 June 2010

?
+---------------------------------+---------------------------------+
| FOR IMMEDIATE RELEASE | 21 June 2010 |
+---------------------------------+---------------------------------+


Lipoxen plc
('Lipoxen' or 'the Company')

Further PolyXenTechnology Patent

- PolyXen patent family strengthened and extended into 2025 -

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, announces today that its monofunctional PSA PolyXen technology grant
has been allowed. The patent extends the PolyXen technology patent family in
the US giving both Lipoxen and its license partners additional patent protection
into 2025.

The monofunctional PSA technology is similar to Lipoxen's other PolyXen
technologies as it enables the attachment of polysialic acid (PSA, a polymer
occurring naturally in humans) to a therapeutic protein, thereby extending its
active life. This process is known as polysialylation and improves drug
performance and longer circulation time of the drug in the body. The resulting
conjugate molecules are biodegradable, non-immunogenic and non-toxic, and
therefore are expected to avoid the toxicity attributed to other methods of
extending active life, such as the use of polyethylene glycol in PEGylated
protein drug candidates.

Importantly, this new patent means that Lipoxen's PolyXen patent family now
covers the creation of therapeutic conjugates utilising both the reducing end,
as well as the non-reducing end, such methodologies having been shown in tests
completed prior to both pre-clinical studies and clinical trials to avoid the
problem of side product contamination.

Commenting on the patent grant, M. Scott Maguire, CEO of Lipoxen, said: "This
new PolyXen technology patent will protect Lipoxen's novel
polysialylationtechnology into 2025. By applying this novel technology to its
partners' therapeutic proteins, it is in the unique position delivering the
benefits of polysialylation such as extending its active life plus the advantage
of avoiding final product contamination. This forms an important part of
Lipoxen's strategy to build its patent portfolio and secure long term value in
the US, world's largest pharmaceutical market."

- Ends -

[buywell2] 15/6/2010 10:18

So Mr Scott Maguire

Perhaps you should concentrate on spending cash on this Baxter partnership and stop spending cash on things that are less likely to happen

[buywell2] 15/6/2010 10:16

FOR IMMEDIATE RELEASE | 14 JUNE 2010 |
+---------------------------------+---------------------------------+



Lipoxen plc
('Lipoxen' or 'the Company')

Baxter Partnering Update

Announcement of Positive Results and Expansion of Collaboration

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the
development of high-value differentiated biologicals, vaccines and siRNA
delivery, is pleased to provide an update on its partnership with Baxter
International Inc., ("Baxter"). This exclusive world-wide development and
licence agreement is based on the PolyXen PSA-Factor VIII project being
developed with Baxter, a world leader in the treatment of haemophilia, for
improved longer-acting forms of blood-clotting factors.

Lipoxen and Baxter continue to move forward on preclinical work using Lipoxen's
PSA technology focused on linking Lipoxen's PolyXen drug delivery technology
with Baxter's proprietary proteins. In recent preclinical models positive
results with PSA-Factor VIII have been shown. These early positive results
provide both Baxter and Lipoxen with confidence in the programme's potential to
transition into clinical development.

Importantly, and as first announced in December 2006, Lipoxen has the potential
to receive up to $73 million in cash milestones plus royalties as the first
candidate progresses through clinical development and commercialisation.

Baxter is also investigating the Lipoxen PSA technology for other
potential factor replacement therapies in the treatment of haemophilia A, B and
for patients with inhibitors. The Factor VIII global market size is
approximately $5 billion whilst the Inhibitor and Factor IX markets were $1.2
billion and $600 million respectively (Sources: Jefferies International /
Datamonitor).

Lipoxen's PolyXen is an enabling technology for protein drug delivery. It uses
the natural polymer polysialic acid (PSA) to prolong the active life and improve
the stability of therapeutic peptides and proteins. It can also be used for
small molecule drugs.

Commenting on this announcement, Scott Maguire, CEO said: "Baxter is one of
Lipoxen's most important partners and the Company's third largest shareholder.
We are extremely encouraged by the results seen to date. In light of the strong
scientific progress that has been made over the last three years, there is clear
potential for both the lead program PSA-Factor VIII but also for broadening this
collaboration for other haemophilia drug therapies. Importantly, progressing
this PSA-Factor-VIII programme alone through the clinic will trigger additional
cash payments to the Company which would significantly advance our objective of
reaching the pivotal cash inflection point in our Company's development to
convert Lipoxen into a cash-generative enterprise. We look forward to providing
a further update on this programme in due course."

[divinausa1] 14/6/2010 10:20

i think the $73m is many years away though?

[drewz] 14/6/2010 09:49

I intend to keep buying whilst it is so cheap.

Anything under 20p is an absolute bargain.

[the go to guy] 11/6/2010 15:29

Personally speaking, I bought at 8p so would be quite happy to see the share price get to 20p though can fully understand why a LTH might be peeved.